| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BridgeBio Pharma, Inc.: Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy | 2 | GlobeNewswire (Europe) | - Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality... ► Artikel lesen | |
| 24.05. | BridgeBio Pharma, Inc.: BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting | 2 | GlobeNewswire (USA) | ||
| 15.05. | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 85 | GlobeNewswire (Europe) | PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and... ► Artikel lesen | |
| 14.05. | BridgeBio Pharma, Inc.: BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 | 1 | GlobeNewswire (USA) | ||
| 13.05. | BridgeBio Pharma, Inc.: BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause ... | 3 | GlobeNewswire (USA) | ||
| 03.05. | BridgeBio Pharma Inc reports results for the quarter ended in March - Earnings Summary | 7 | Reuters | ||
| 02.05. | BridgeBio Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.05. | BridgeBio Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.04. | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 114 | GlobeNewswire (Europe) | PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases... ► Artikel lesen | |
| 07.04. | BridgeBio Pharma, Inc.: BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 97 | GlobeNewswire (Europe) | - In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression... ► Artikel lesen | |
| 20.03. | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 90 | GlobeNewswire (Europe) | PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio"or the"Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and... ► Artikel lesen | |
| 06.03. | BridgeBio Pharma, Inc.: BridgeBio Pharma Announces Pricing of Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
| 04.03. | BridgeBio Pharma, Inc.: BridgeBio Pharma Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 04.03. | BridgeBio Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | BridgeBio Pharma, Inc.: BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM | 519 | GlobeNewswire (Europe) | - BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according... ► Artikel lesen | |
| 22.02. | BridgeBio Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 22.02. | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update | 174 | GlobeNewswire (Europe) | - Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase... ► Artikel lesen | |
| 22.02. | BridgeBio Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.02. | BridgeBio Pharma, Inc.: BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan | 260 | GlobeNewswire (Europe) | - BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive upfront payment of USD 100 million with royalties... ► Artikel lesen | |
| 06.02. | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 122 | GlobeNewswire (Europe) | PALO ALTO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NEL | 2.691 |
| EVOTEC | 1.941 |
| NVIDIA | 1.847 |
| VOLKSWAGEN | 1.701 |
| SALESFORCE | 1.334 |
| BAYER | 1.296 |
| TUI | 1.242 |
| GAMESTOP | 1.099 |
| PLUG POWER | 1.011 |
| UIPATH | 787 |
| DELL TECHNOLOGIES | 771 |
| BYD | 745 |
| BIONTECH | 678 |
| RHEINMETALL | 650 |
| AIXTRON SE | 623 |
| DEUTSCHE LUFTHANSA | 596 |
| JINKOSOLAR | 561 |
| SUPER MICRO COMPUTER | 545 |
| PALANTIR TECHNOLOGIES | 503 |
| TESLA | 468 |
| HELLOFRESH | 466 |
| SIEMENS ENERGY | 465 |
| BASF | 428 |
| MERCEDES-BENZ | 422 |
| PAYPAL | 411 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
